药明康德(02359) - 2023 Q1 - 季度业绩

Financial Performance - The company reported a total revenue of RMB 8,963,741,607.53 for Q1 2023, representing a year-on-year increase of 5.77%[6] - Net profit attributable to shareholders reached RMB 2,168,128,379.15, marking a significant increase of 31.97% compared to the previous year[6] - The adjusted net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 1,868,816,896.68, reflecting a 9.02% increase year-on-year[6] - Basic earnings per share were RMB 0.74, up by 32.14% year-on-year, while diluted earnings per share were RMB 0.72, increasing by 35.85%[6] - Total comprehensive income for Q1 2023 was RMB 2.17 billion, up from RMB 1.65 billion in Q1 2022, marking a 31.6% increase[28] - Net profit for Q1 2023 was RMB 2.19 billion, up 31.8% from RMB 1.66 billion in Q1 2022[27] - Operating profit for Q1 2023 was RMB 2.62 billion, compared to RMB 2.00 billion in Q1 2022, reflecting a 30.6% increase[26] - The company reported a net profit of 2,168,129 thousand RMB for Q1 2023, compared to 1,642,947 thousand RMB in Q1 2022, which is an increase of about 32%[38] Cash Flow and Assets - The net cash flow from operating activities surged to RMB 3,027,329,258.18, an impressive increase of 508.55% compared to the same period last year[6] - Cash flow from operating activities for Q1 2023 was RMB 3.03 billion, significantly higher than RMB 497.47 million in Q1 2022[30] - The company incurred a net cash outflow from investing activities of RMB 1,222,881,147.89 in Q1 2023, contrasting with a net inflow of RMB 1,474,723,859.12 in Q1 2022[31] - The company’s financing activities generated a net cash inflow of RMB 148,902,292.20 in Q1 2023, down from RMB 387,302,550.67 in Q1 2022[31] - The company’s cash and cash equivalents increased to RMB 9,867,844,029.10 by the end of Q1 2023, up from RMB 7,983,904,283.09 at the beginning of the quarter[34] - The company's cash and cash equivalents increased to 9,867,844 thousand RMB by the end of Q1 2023, compared to 7,026,525 thousand RMB at the end of Q1 2022, marking a growth of about 40%[37] Revenue Breakdown - Revenue from the chemical business reached RMB 6,432.8 million, a 5.1% increase compared to RMB 6,118.0 million in the same period last year[12] - The testing business generated revenue of RMB 1,452.9 million, reflecting a year-on-year growth of 13.6%[13] - The biology business achieved revenue of RMB 577.0 million, an increase of 8.3% compared to RMB 532.6 million in the same period of 2022[14] - The cell and gene therapy CTDMO business generated revenue of RMB 324.5 million, up 8.7% from RMB 298.6 million year-over-year[15] - Revenue from U.S. customers was RMB 5.41 billion, a 3% increase year-on-year, and a 22% increase when excluding COVID-19 commercialization projects[10] - Revenue from European customers grew by 19% year-on-year, reaching RMB 1.44 billion[10] Assets and Liabilities - Total assets as of March 31, 2023, amounted to RMB 68,188,088,624.62, a 5.41% increase from the end of the previous year[6] - The total liabilities as of March 31, 2023, were ¥18,357,086,099.46, compared to ¥17,763,654,011.21 at the end of 2022, representing a rise of approximately 3.3%[24] - The total current liabilities rose from 14,499,361 thousand RMB as of December 31, 2022, to 15,786,216 thousand RMB as of March 31, 2023, indicating an increase of approximately 8.87%[35] - The total equity attributable to shareholders increased to ¥49,474,882,627.12 from ¥46,589,953,393.31, showing a growth of approximately 6.3%[25] Business Operations and Strategy - The company serves over 6,000 active clients from more than 30 countries through 32 operational bases globally[4] - The workforce consists of 43,800 employees, with 13,147 holding master's degrees or higher, and 1,426 holding doctoral degrees[4] - The company continues to focus on talent retention through recruitment, training, and promotion to maintain high service standards and industry leadership[5] - The company added over 310 new customers in Q1 2023, bringing the total active customer count to over 6,000[10] - The company expects a revenue growth of 5-7% for the full year of 2023, based on current order status[17] - The company has completed IND applications for 175 projects and obtained CTA approvals for 150 projects as of the end of Q1 2023[16] - The company has developed a new drug for treating COVID-19, which has been approved for market launch in March 2023[16] - The company anticipates achieving approximately 50% compound growth rate in revenue from drug sales sharing agreements over the next decade[16] Research and Development - R&D expenses increased to RMB 357.30 million in Q1 2023, up from RMB 280.04 million in Q1 2022, representing a 27.6% rise[26] - The company has delivered over 260 ADC drug projects, establishing a comprehensive capability platform from early discovery to preclinical efficacy research[14] - The company is supporting 68 projects in the CTDMO service platform, including 52 preclinical and clinical phase I projects[15] - The new molecular-related revenue in the biology segment grew strongly by 40%, accounting for 25.3% of the total biology business revenue[14]